Stockscreener 앱 받기
2.56
1.59%
0.04
시간 외 거래:
2.60
0.04
+1.56%
전일 마감가:
$2.52
열려 있는:
$2.65
하루 거래량:
1.24M
Relative Volume:
1.19
시가총액:
$277.33M
수익:
$27.08M
순이익/손실:
$-37.00M
주가수익비율:
-4.9231
EPS:
-0.52
순현금흐름:
$-18.46M
1주 성능:
+9.40%
1개월 성능:
+37.63%
6개월 성능:
+77.78%
1년 성능:
+22.49%
1일 변동 폭
$2.40
$2.70
1주일 범위
$2.24
$2.70
52주 변동 폭
$1.05
$5.17
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
명칭
Aclaris Therapeutics Inc
전화
484-324-7933
주소
701 LEE ROAD, WAYNE, PA
ACRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
2.56 | 273.00M | 27.08M | -37.00M | -18.46M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 재개 | Piper Sandler | Overweight |
| 2025-05-28 | 개시 | Wedbush | Outperform |
| 2025-03-18 | 재개 | Cantor Fitzgerald | Overweight |
| 2024-12-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2024-11-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-19 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | 개시 | Evercore ISI | Outperform |
| 2022-12-14 | 개시 | Stifel | Buy |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2022-10-06 | 개시 | BTIG Research | Buy |
| 2021-07-23 | 재개 | Jefferies | Buy |
| 2021-06-15 | 개시 | Piper Sandler | Overweight |
| 2021-04-21 | 개시 | H.C. Wainwright | Buy |
| 2019-10-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | 개시 | SVB Leerink | Outperform |
| 2018-03-28 | 재개 | Leerink Partners | Outperform |
| 2018-02-09 | 개시 | Guggenheim | Buy |
| 2017-06-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-11-29 | 개시 | Leerink Partners | Outperform |
| 2016-09-30 | 개시 | JMP Securities | Mkt Outperform |
| 2016-06-10 | 개시 | Guggenheim | Buy |
| 2015-11-02 | 개시 | Citigroup | Buy |
| 2015-11-02 | 개시 | Jefferies | Buy |
모두보기
Aclaris Therapeutics Inc 주식(ACRS)의 최신 뉴스
Will Aclaris Therapeutics Inc. stock outperform international peersTrade Ideas & Risk Managed Investment Entry Signals - newser.com
Key resistance and support levels for Aclaris Therapeutics Inc.2025 Geopolitical Influence & Free Technical Pattern Based Buy Signals - newser.com
Understanding Aclaris Therapeutics Inc.’s price movement2025 Top Gainers & High Yield Stock Recommendations - newser.com
Applying chart zones and confluence areas to Aclaris Therapeutics Inc.Dollar Strength & AI Enhanced Execution Alerts - newser.com
Will Aclaris Therapeutics Inc. stock deliver shareholder valueJuly 2025 Weekly Recap & Fast Gain Stock Trading Tips - newser.com
Can Aclaris Therapeutics Inc. stock deliver strong Q4 earningsJuly 2025 Selloffs & AI Enhanced Trading Alerts - newser.com
Risk adjusted return profile for Aclaris Therapeutics Inc. analyzedStop Loss & Fast Momentum Entry Tips - newser.com
Statistical indicators supporting Aclaris Therapeutics Inc.’s strengthWatch List & Long Hold Capital Preservation Plans - newser.com
Why Aclaris Therapeutics Inc. (8AT) stock is a must watch tickerPortfolio Update Summary & AI Forecasted Stock Moves - newser.com
Why Aclaris Therapeutics Inc. (8AT) stock gets analyst attentionPortfolio Update Report & Proven Capital Preservation Methods - newser.com
Will Aclaris Therapeutics Inc. (8AT) stock hit Wall Street targetsWeekly Profit Report & Fast Moving Stock Watchlists - newser.com
How Aclaris Therapeutics Inc. (8AT) stock performs during market turbulenceJuly 2025 News Drivers & Fast Entry Momentum Alerts - newser.com
Using Python tools to backtest Aclaris Therapeutics Inc. strategiesJuly 2025 Analyst Calls & AI Enhanced Trading Signals - newser.com
Why Aclaris Therapeutics Inc. stock attracts global investorsMarket Sentiment Review & Verified Momentum Watchlists - newser.com
Can you recover from losses in Aclaris Therapeutics Inc.Rate Cut & Safe Capital Growth Stock Tips - newser.com
Aclaris Therapeutics (NASDAQ:ACRS) adds US$40m to market cap in the past 7 days, though investors from three years ago are still down 83% - Yahoo Finance
How Aclaris Therapeutics Inc. stock trades before earningsWeekly Profit Report & Daily Stock Momentum Reports - newser.com
Is Aclaris Therapeutics Inc. stock a contrarian buy2025 Valuation Update & Fast Exit Strategy with Risk Control - newser.com
How to use a screener to detect Aclaris Therapeutics Inc. breakoutsJuly 2025 Big Picture & Expert Curated Trade Setup Alerts - newser.com
Will Aclaris Therapeutics Inc. benefit from macro trendsJuly 2025 Setups & Technical Confirmation Trade Alerts - newser.com
Is Aclaris Therapeutics Inc. (8AT) stock a momentum leaderAnalyst Downgrade & Low Risk Profit Maximizing Plans - newser.com
What drives Aclaris Therapeutics Inc stock priceContrarian Investment Ideas & Investment Recommendations You Can Trust - earlytimes.in
Aclaris Therapeutics Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Will Aclaris Therapeutics Inc. (8AT) stock benefit from mergersQuarterly Performance Summary & Expert Curated Trade Ideas - newser.com
Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 31% But Its Business Is Yet to Catch Up - 富途牛牛
Revenues Not Telling The Story For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Shares Rise 31% - simplywall.st
Aclaris Therapeutics’ ATI-045 Study: A Potential Game-Changer for Atopic Dermatitis - TipRanks
Will Aclaris Therapeutics Inc. stock outperform Dow Jones indexMarket Risk Analysis & Low Risk Investment Opportunities - newser.com
Aclaris Therapeutics Inc (ACRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Aclaris Therapeutics Inc 주식 (ACRS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mehra Anand | Director |
Nov 19 '24 |
Buy |
2.25 |
666,666 |
1,499,998 |
710,030 |
0.64%
0.35%
자본화:
|
볼륨(24시간):